Price to Operating Profit (P/OP)
since 2005
Paying user area
Try for free
Edwards Lifesciences Corp. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Edwards Lifesciences Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Edwards Lifesciences Corp., P/OP, long-term trends, calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Operating income1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2010 | = | ÷ | = | ÷ | |||||||
| Mar 2, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 9, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Edwards Lifesciences Corp. Annual Report.
- Share Price Trend
- The share price exhibited an overall upward trajectory from 2006 through 2022. Starting at $3.48 in 2006, it increased gradually with some fluctuations, reaching $7.65 in 2010 and doubling to $14.17 in 2011. After a slight dip in 2012, the price recovered to $14.32 in 2013, followed by minor declines and consolidations in the next few years. From 2014 onwards, the share price demonstrated strong growth, surging to $22.41 and continuing this upward trend with a peak at $107.73 in 2022.
- Operating Profit per Share (Operating Profit)
- Data for operating profit per share is available only from 2017 onwards. The value showed variability, starting at $1.18 in 2017 and increasing to $1.73 in 2018. It then decreased back near the initial level in 2019 to $1.2 before rising again to $1.83 in 2020. The trend saw another dip to $1.44 in 2021, followed by a significant increase to $2.71 in 2022, indicating improved operating profitability per share in the latest year.
- Price to Operating Profit (P/OP) Ratio
- The P/OP ratio data also begins in 2017 and reveals fluctuating valuation multiples over recent years. Initially, the ratio was around 25 in 2017 and 2018, rising sharply to nearly 50 in 2019. It decreased to approximately 42 in 2020, then increased again to almost 61 in 2021 before declining substantially to below 40 in 2022. These changes suggest varying investor sentiment and expectations relative to the company's operating profit performance.
- Insights and Observations
- The progressive increase in share price over the analyzed period reflects a positive market perception and potential growth in company value. The variation in operating profit per share from 2017 to 2022 indicates some volatility in profitability, although the most recent year shows significant improvement. The P/OP ratio's fluctuations imply a dynamic relationship between share price and operating profit, possibly driven by broader market conditions, company performance, or investor expectations. The declining P/OP ratio in 2022, despite higher profit per share, may point to a more conservative valuation or market adjustment occurring during that period.
Comparison to Competitors
Edwards Lifesciences Corp., P/OP, long-term trends, comparison to competitors
| Edwards Lifesciences Corp. | Abbott Laboratories | CVS Health Corp. | Intuitive Surgical Inc. | Medtronic PLC | UnitedHealth Group Inc. | |
|---|---|---|---|---|---|---|
| Feb 14, 2022 | ||||||
| Feb 12, 2021 | ||||||
| Feb 14, 2020 | ||||||
| Feb 15, 2019 | ||||||
| Feb 16, 2018 | ||||||
| Feb 17, 2017 | ||||||
| Feb 19, 2016 | ||||||
| Feb 20, 2015 | ||||||
| Feb 28, 2014 | ||||||
| Feb 28, 2013 | ||||||
| Feb 27, 2012 | ||||||
| Feb 28, 2011 | ||||||
| Feb 26, 2010 | ||||||
| Mar 2, 2009 | ||||||
| Feb 29, 2008 | ||||||
| Mar 1, 2007 | ||||||
| Mar 9, 2006 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).